Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001017215 | SCV001178256 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-02-14 | criteria provided, single submitter | clinical testing | The c.1073dupA pathogenic mutation, located in coding exon 8 of the ATM gene, results from a duplication of A at nucleotide position 1073, causing a translational frameshift with a predicted alternate stop codon (p.N358Kfs*2). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
| Invitae | RCV001052221 | SCV001216421 | pathogenic | Ataxia-telangiectasia syndrome | 2023-12-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn358Lysfs*2) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 822123). For these reasons, this variant has been classified as Pathogenic. |
| Myriad Genetics, |
RCV004030392 | SCV004932793 | pathogenic | Familial cancer of breast | 2024-01-12 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |